- Home
- ASG vs ABEO Comparison
ASG vs ABEO Comparison
Compare ASG & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ASG | ABEO |
|---|---|---|
| Founded | N/A | 1974 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.4M | 280.2M |
| IPO Year | 1995 | 2005 |
Fundamental Metrics
Financial Performance| Metric | ASG | ABEO |
|---|---|---|
| Price | $4.77 | $4.31 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $18.75 |
| AVG Volume (30 Days) | 279.5K | ★ 1.4M |
| Earning Date | 01-01-0001 | 03-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 165.16 |
| EPS | N/A | ★ 1.01 |
| Revenue | N/A | ★ $2,998,000.00 |
| Revenue This Year | N/A | $1,276.65 |
| Revenue Next Year | N/A | $112.53 |
| P/E Ratio | ★ N/A | $4.38 |
| Revenue Growth | N/A | ★ 258.18 |
| 52 Week Low | $4.01 | $3.93 |
| 52 Week High | $5.69 | $7.54 |
Technical Indicators
Market Signals| Indicator | ASG | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 36.95 | 32.88 |
| Support Level | N/A | $4.00 |
| Resistance Level | $5.57 | $5.62 |
| Average True Range (ATR) | 0.08 | 0.22 |
| MACD | -0.01 | -0.06 |
| Stochastic Oscillator | 13.11 | 3.41 |
Price Performance
Historical ComparisonAbout ASG Liberty All-Star Growth Fund Inc.
Liberty All Star Growth Fund Inc is the United States based diversified, closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment in a diversified portfolio of equity securities. The company portfolio of investments consists of different industries such as consumer discretionary, consumer staples, healthcare, industrial, information technology and others.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.